A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic

Matt Church

Division of Cancer Sciences

Research output: Contribution to conference › Abstract › peer-review

Original language	English
DOIs	https://doi.org/10.1016/s0169-5002(21)00276-2
Publication status	Published - Jun 2021

Access to Document

10.1016/s0169-5002(21)00276-2

Other files and links

http://dx.doi.org/10.1016/s0169-5002(21)00276-2

Cite this